tirabrutinib + idelalisib

tirabrutinib + idelalisib is an oral, small molecule combination therapy comprising tirabrutinib, a second-generation, selective irreversible inhibitor of Bruton’s tyrosine kinase (BTK), and idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). The combination targets two pivotal signaling nodes in the B-cell receptor (BCR) pathway, aiming to block complementary survival and proliferation signals in malignant B-cells. This dual targeting is designed to improve response depth and overcome single-agent resistance in relapsed or refractory B-cell malignancies, primarily chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. The regimen has demonstrated tolerable safety and promising antitumor activity in phase 1b/2 trials, but with noted toxicities including infections and transaminitis typical of PI3K inhibitors.